跳至主要内容
临床试验/NCT06319391
NCT06319391进行中(未招募)不适用

Analysis of the Effect of Donor CYP3A5 Gene Polymorphism on Early Tacrolimus Concentration and Postoperative Acute Renal Injury After Liver Transplantation

Ziqiang Li1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
60
试验地点
1
主要终点
Fk506

研究概览

简要总结

Tacrolimus is the most commonly used immunosuppressant for preventing and treating rejection after liver transplantation. However, its treatment window is narrow, the pharmacokinetic individual differences are large, routine dose according to body weight, sometimes low dose will cause graft rejection of patients, or high dose will lead to infection and liver and kidney toxicity and other adverse reactions. Moreover, the conventional drug testing can not fully reflect the efficacy of tacrolimus, and there are shortcomings of lag, experience and passivity. FK506 is metabolized primarily by cytochrome P450 member 3A5 in the liver and intestines. CYP3A5*3 is the most important factor determining the expression level of CYP3A5. This mutation can cause variable shear and produce unstable protein, so that patients carrying CYP3A5*3/*3 gene do not express CYP3A5. Acute kidney injury is a common and important complication after liver transplantation. Despite recent advances in organ preservation, surgical techniques, and immunosuppressive protocols, the incidence of AKI after orthotopic liver transplantation remains high. AKI has a significant impact on both short - and long-term prognosis of orthotopic liver transplantation recipients. Studies have shown that orthotopic liver transplantation recipients with AKI have significantly higher mortality rates in hospital, at 28 days and at 1 year after surgery than those without AKI. In this study, the relationship between donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration was investigated, and the effect of donor and recipient CYP3A5 gene polymorphism and tacrolimus concentration on acute kidney injury after liver transplantation was investigated. To provide guidance for individual administration of gene-directed tacrolimus in patients, and provide basis for prevention and reduction of postoperative acute kidney injury in liver transplantation patients.

研究设计

研究类型
Observational
观察模型
Cohort
时间视角
Retrospective

入排标准

性别
All
接受健康志愿者

入选标准

  • Patients undergoing orthotopic liver transplantation in our center.
  • The postoperative immunosuppression regimen was tacrolimus、methylprednisolone and balipremumab for injection in all cases,and no drugs that interacted with tacrolimus were used.
  • The postoperative follow-up time was greater than 6 months and no serious rejection occurred during the follow-up period.

排除标准

  • Combined organ transplantation.
  • liver transplant patients on other immunosuppressive regimens.
  • Preoperative CKD or need RRT.
  • Preoperative serum creatinine (SCr) > 133 mol/L.
  • Loss of follow-ups.

结局指标

主要结局

Fk506

时间窗: 1-28 days postoperatively

Tacrolimus concentration

Scr

时间窗: 1-28 days postoperatively

Reflects indicators of kidney function

次要结局

未报告次要终点

研究者

发起方
Ziqiang Li
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Ziqiang Li

professor

Qianfoshan Hospital

研究点 (1)

Loading locations...

相似试验